|

ALNYLAM PHARMACEUTICALS INC (ALNY)

US02043Q1076 - Common Stock

161.36  +2.16 (+1.36%)

After market: 161.36 0 (0%)

News Image
16 days ago - Seeking Alpha

Alnylam reports positive Phase 2 data for hypertension drug (NASDAQ:ALNY)

Alnylam Pharmaceuticals announces positive Phase 2 study results for zilebesiran, a potential treatment for hypertension and high cardiovascular risk.

News Image
21 days ago - SBWire

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws

San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

News Image
26 days ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

News Image
26 days ago - Market News Video

ALNY May 2024 Options Begin Trading

News Image
a month ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

News Image
a month ago - Investor's Business Daily

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

The company can begin a pivotal study of its treatment for cardiomyopathy.

News Image
a month ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

News Image
2 months ago - Seeking Alpha

Alnylam stock downgraded at Oppenheimer (NASDAQ:ALNY)

Oppenheimer downgrades Alnylam Pharmaceuticals as it prepares to release data from its HELIOS-B study for amyloidosis therapyvutrisiran early next year. Read more here.

News Image
2 months ago - Market News Video

Notable Monday Option Activity: ALNY, SPOT, DDOG

News Image
2 months ago - Seeking Alpha

Arbutus stock lower after FDA snub for Alnylam drug

The FDA rejection of Alnylam's amyloidosis therapy impacts Arbutus Biopharma, which has a licensing deal with the company for the product. Read more here.

News Image
2 months ago - Investor's Business Daily

Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug

Shares skidded to their lowest point since September on the FDA's rejection.

News Image
2 months ago - The Motley Fool

2 Growth Stocks That Could Rocket Higher Before the End of 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

News Image
2 months ago - Seeking Alpha

Ionis, AbbVie, Alnylam draw bullish views at Raymond James (NYSE:ABBV)

Raymond James initiated coverage on Ionis Pharmaceuticals, AbbVie, and Alnylam Pharmaceuticals with buy-equivalent ratings. Read more here.

News Image
3 months ago - Seeking Alpha

Alnylam stock falls after FDA panel questions drug's effectiveness (ALNY)

Alnylam (ALNY) stock was down 8% Thursday, the day after an FDA advisory panel questioned the effectiveness of its drug patisiran in treating ATTR-CM. Read more here.